HER2-positive Breast Cancer Registry
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
HER2 + Breast Cancer
Overall survival rate, For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis., From diagnosis to 5 years after diagnosis
Pathologic complete response rate, Percentage of patients with stage I-III HER2-positive breast cancer who received neoadjuvant systemic therapy and experienced pathologic complete response., From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.